Alexion Pharmaceuticals is a biopharmaceutical company. Co.'s marketed product, Soliris® (eculizumab), is a therapeutic approved for patients with disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, a genetic blood disorder; and atypical hemolytic uremic syndrome, a genetic disease. Co.'s clinical programs also include: Asfotase Alfa, a targeted enzyme replacement therapy in clinical trials for patients with Hypophosphatasia; and a pre-Investigational New Drug toxicology study of cyclic Pyranopterin Monophosphate replacement therapy for the treatment of Molybdenum Cofactor Deficiency Disease Type A.
Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20
minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.